Senseonics Holdings Inc. ( (SENS) ) has released its Q2 earnings. Here is a breakdown of the information Senseonics Holdings Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Senseonics Holdings, Inc. is a medical technology company specializing in the development and manufacturing of long-term, implantable continuous glucose monitoring systems for individuals with diabetes. The company is known for its innovative Eversense CGM systems, which provide continuous glucose data to users via a smartphone app.
In its latest earnings report, Senseonics Holdings, Inc. announced a significant year-over-year revenue growth of 37% for the second quarter of 2025, totaling $6.6 million. This growth was largely driven by a 79% increase in new patient starts in the U.S. The company also highlighted strategic initiatives such as an expanded direct-to-consumer advertising campaign and a commercial development agreement with Sequel Med Tech.
Key financial performance metrics included a gross profit of $3.1 million, a substantial increase from the previous year’s $0.3 million, attributed to improved margins and a one-time tax gain. Research and development expenses saw a notable decrease, while selling, general, and administrative expenses rose slightly due to increased sales commissions and personnel costs. The net loss for the quarter was reduced to $14.5 million, down from $20.3 million in the prior year.
Looking ahead, Senseonics maintains its full-year 2025 revenue guidance of $34-38 million, anticipating a doubling of its global patient base. The company expects increased revenue in the latter half of the year, driven by the Eversense 365 product launch and ongoing marketing efforts. Gross margins are projected to improve, and cash used in operations is estimated at approximately $60 million for the year.